Vinayak Venkataraman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytic Sarcoma | 2 | 2021 | 44 | 1.480 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2022 | 689 | 1.250 |
Why?
|
| Blast Crisis | 2 | 2021 | 103 | 0.920 |
Why?
|
| Oximes | 1 | 2020 | 311 | 0.640 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 380 | 0.610 |
Why?
|
| Pyrimidinones | 1 | 2020 | 371 | 0.600 |
Why?
|
| Informed Consent | 1 | 2024 | 995 | 0.590 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 643 | 0.590 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 407 | 0.530 |
Why?
|
| Pyridones | 1 | 2020 | 712 | 0.510 |
Why?
|
| Motivation | 1 | 2024 | 1971 | 0.470 |
Why?
|
| Imidazoles | 1 | 2020 | 1206 | 0.460 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 2043 | 0.450 |
Why?
|
| Sarcoma | 2 | 2021 | 1897 | 0.440 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 1581 | 0.420 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1061 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1270 | 0.400 |
Why?
|
| Mutation, Missense | 1 | 2020 | 2564 | 0.370 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13695 | 0.370 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 379 | 0.200 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2021 | 30 | 0.200 |
Why?
|
| Intention | 1 | 2024 | 341 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2023 | 776 | 0.170 |
Why?
|
| Goals | 1 | 2024 | 706 | 0.160 |
Why?
|
| Benzamides | 1 | 2023 | 1379 | 0.150 |
Why?
|
| Parkinson Disease | 3 | 2015 | 2775 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 1791 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 21683 | 0.120 |
Why?
|
| Telemedicine | 4 | 2015 | 2872 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1782 | 0.110 |
Why?
|
| Disease Management | 2 | 2021 | 2459 | 0.110 |
Why?
|
| Piperazines | 1 | 2023 | 2488 | 0.110 |
Why?
|
| Device Approval | 1 | 2014 | 163 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 2109 | 0.100 |
Why?
|
| Equipment and Supplies | 1 | 2014 | 281 | 0.100 |
Why?
|
| Motor Skills | 1 | 2015 | 522 | 0.100 |
Why?
|
| Health | 1 | 2014 | 394 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2023 | 2942 | 0.100 |
Why?
|
| Movement Disorders | 1 | 2014 | 445 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2022 | 3461 | 0.090 |
Why?
|
| Gait | 1 | 2015 | 793 | 0.090 |
Why?
|
| Mutation | 3 | 2023 | 29786 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5535 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 1681 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 5172 | 0.080 |
Why?
|
| Videoconferencing | 3 | 2014 | 195 | 0.080 |
Why?
|
| Neurology | 1 | 2015 | 763 | 0.070 |
Why?
|
| Huntington Disease | 1 | 2014 | 1124 | 0.070 |
Why?
|
| Humans | 15 | 2024 | 744343 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 5442 | 0.070 |
Why?
|
| Young Adult | 2 | 2024 | 56430 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 1622 | 0.060 |
Why?
|
| Incidence | 1 | 2022 | 20947 | 0.060 |
Why?
|
| Male | 8 | 2022 | 350118 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 6993 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2014 | 4043 | 0.050 |
Why?
|
| Internet | 1 | 2012 | 3064 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2014 | 5078 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
| Research Design | 1 | 2015 | 5987 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 35136 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2015 | 8324 | 0.040 |
Why?
|
| Middle Aged | 6 | 2022 | 213383 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 63114 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 77449 | 0.030 |
Why?
|
| Insurance | 1 | 2014 | 111 | 0.030 |
Why?
|
| Female | 6 | 2022 | 380194 | 0.030 |
Why?
|
| Fingers | 1 | 2015 | 513 | 0.030 |
Why?
|
| Voice | 1 | 2015 | 259 | 0.020 |
Why?
|
| House Calls | 1 | 2013 | 160 | 0.020 |
Why?
|
| Posture | 1 | 2015 | 958 | 0.020 |
Why?
|
| Models, Economic | 1 | 2014 | 713 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2014 | 430 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2021 | 2725 | 0.020 |
Why?
|
| Reaction Time | 1 | 2015 | 2097 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 19905 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 5720 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13284 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 2714 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2014 | 1901 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 6038 | 0.010 |
Why?
|
| Aged | 4 | 2015 | 163280 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14722 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15540 | 0.010 |
Why?
|
| Child | 1 | 2021 | 77709 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 40075 | 0.010 |
Why?
|
| United States | 1 | 2014 | 69872 | 0.000 |
Why?
|
| Adult | 1 | 2014 | 214055 | 0.000 |
Why?
|